-
Study aim
-
Determining the Effect of Colchicine on the Prevention of Atrial Fibrillation after Coronary Artery Bypass Grafting(CABG)
-
Design
-
Clinical trial with control group, with parallel groups, double-blind, phase 2 on 230 patients
-
Settings and conduct
-
Fatemeh Zahra Sari Heart Center, affiliated to Mazandaran University of Medical Sciences, in this study, a data collection form designed by the research team will be used to collect information. In the first part, demographic Characteristics of Patients and in the second part, related information. The patient will be recorded for Hospitalization and Treatment such as Atrial Fibrillation, number of Days hospitalized in the ICU, number of Days hospitalized and the incidence of complications due to Colchicine consumption such as gastrointestinal intolerance, etc. Patients and outcome analysts are blinded.
-
Participants/Inclusion and exclusion criteria
-
Entry conditions: All of the Patients with Coronary Artery Disease that are Candidates for Coronary Artery Bypass Grafting surgery
-
Intervention groups
-
In this Study, 230 Patients with Entry Conditions will be randomly divided into two Groups of Patients receiving Colchicine and the Control Group. Patients in the first Group, will be given 0.5 mg of Colchicine every 12 hours for 48 hours before surgery, and 0.5 mg daily if they weigh less than 70 kg, until discharge. Patients in the second group will also be given a placebo, similar to the conditions in the first group.
-
Main outcome variables
-
Duration of ICU hospitalization, Duration of hospitalization, Atrial fibrillation